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We wanted to compare the efﬁcacy of haploidentical hematopoietic stem cell transplantation (HSCT) with
chemotherapy alone in adults with standard-risk acute lymphoblastic leukemia (ALL) in ﬁrst complete remis-
sion (CR1). One hundred thirty-eight consecutive adult patients with standard-risk ALL in CR1 were retro-
spectively investigated. Of these patients, 59 received chemotherapy alone (group A) and 79 received
unmanipulated haploidentical HSCT (group B). Cumulative incidence of relapse at 5 years in group A was
signiﬁcantly higher than that in group B (66.3% versus 29.9%, P < .0001). Overall and disease-free survival in
group A were signiﬁcantly inferior to group B (P < .0001). Moreover, multivariate analyses demonstrated that
central nervous system leukemia (P ¼ .002), T cell immunophenotype (P ¼ .044), expression of E2A-PBX1
(P ¼ .007), and positive minimal residual disease after the ﬁrst cycle of consolidation (P ¼ .004) were corre-
lated with relapse. Patients with 1 of 4 risk factors were assigned to the high-risk group. Otherwise, patients
without risk factors were assigned to the low-risk group. In the high-risk group, HSCT had lower relapse rates
and superior DFS compared with chemotherapy (P < .05), but in the low-risk group, there were no differences
between HSCT and chemotherapy (P > .05). This study is the ﬁrst to demonstrate that compared with chemo-
therapy alone, haploidentical HSCT is a better postremission therapy in adults with standard-risk ALL in CR1.
Moreover, based on the 4 risk factors, the establishment of risk stratiﬁcation could identify the subgroup of
patients with a higher risk of relapse in adults with standard-risk ALL in CR1. Furthermore, risk stratiﬁcation
edirected postremission therapies using haploidentical HSCT or chemotherapy alone not only reduce relapse
rate but also avoid unnecessary treatment-related mortality and improve survival.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Although treatment results in adult acute lymphoblastic
leukemia (ALL) have improved over the past 3 decades, with
complete remission (CR) rates increasing to 85% to 90%, only
30% to 40% of patients survives after 5 years [1-4]. Moreover,
40% to 50% of patients without any known high-risk features
of ALL still develop relapse during follow-up [5]; after
relapse, overall survival (OS) at 5 years is only 7%, and me-
dian survival is only 24 weeks [6]. Even in patients receivingedgments on page 1320.
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14.04.011allogeneic HSCT (allo-HSCT), the OS at 5 years after relapse is
also only 15% to 25% [6]. Therefore, reducing the relapse rate
is still the major goal of treatment optimization in adult ALL.
However, in adult ALL patients, there is still uncertainty
regarding the optimal postremission therapy, which
included consolidation chemotherapy, autologous HSCT
(auto-HSCT), and allo-HSCT.
The strategy of using allo-HSCT, including HLA-identical
sibling HSCT and unrelated HSCT, has been shown to
beneﬁt adult patients with high-risk ALL in ﬁrst CR (CR1)
[3,5,7]. Moreover, some studies have shown that the
outcome of adults with standard-risk ALL in CR1 treatedwith
HLA-identical sibling HSCT is better than those treated with
chemotherapy alone [7,8]. Cumulative incidences of relapse
were 24% for HLA-identical sibling HSCT and 55% forTransplantation.
Figure 1. Diagrams of intervention strategies (A) and patient subgroups (B).
C.-H. Yan et al. / Biol Blood Marrow Transplant 20 (2014) 1314e1321 1315chemotherapy alone (P < .001). Disease-free survival (DFS)
was also signiﬁcantly better in the HSCT group than in
the chemotherapy group (60% versus 42%, P ¼ .01) [8].
However, lack of HLA-identical siblings or unrelated donors
has restricted the application of allo-HSCT in adult ALL
patients.
During last decade, the efﬁcacy and safety of hap-
loidentical HSCT in the treatment of leukemia patients have
been conﬁrmed [9-13]. Our previous study has already
demonstrated that haploidentical HSCT is associated with
comparable relapse rates (13% versus 18%, P ¼ .40),
transplant-related mortality (22% versus 14%, P ¼ .10), OS
(71% versus 72%, P ¼ .72) and DFS (64% versus 71%, P ¼ .27)
with HLA-identical sibling HSCT [9]. However, the compari-
son between haploidentical HSCT and chemotherapy alone
used as postremission treatment of adult standard-risk ALL
patients in CR1 has not been investigated until now. There-
fore, this study was performed to compare the efﬁcacy and
safety of haploidentical HSCT with chemotherapy alone used
as postremission treatment of adult standard-risk ALL pa-
tients in CR1.
METHODS
Eligibility Criteria
Consecutive patients diagnosed with ALL in Peking University Institute
of Hematology from January 1, 2000 to May 30, 2013 who had complete
morphology, immunophenotype, cytogenetic, and molecular data at diag-
nosis were enrolled if they met the following criteria: (1) age 15 to 60 years;
(2) without high-risk features, which consisted of elevated WBC count
(30 109/L for B cell lineage or100 109/L for Tcell lineage), or high-risk
cytogenetic abnormalities, determined according to the National Compre-
hensive Cancer Network 2013 guidelines, such as hypodiploidy, complex
karyotype (5 chromosomal abnormalities), t(9;22) or BCR-ABL, t(v;11q23)
ormixed lineage leukemia (MLL) rearrangements; and (3) achieving CR after
1 to 2 cycles of induction chemotherapy. The study was approved by the
Ethics Committee of Peking University People’s Hospital, and written
informed consent was obtained from all subjects in accordance with the
Declaration of Helsinki.
Study Protocol
Intervention strategies for ALL patients
First, all patients received 1 to 2 cycles of induction chemotherapy. If
patients achieved CR, they received 2 cycles of consolidation chemotherapy;
otherwise, they received salvage chemotherapy. Subsequently, if patients
met the eligibility criteria after 2 cycles of consolidation chemotherapy, they
were divided into 2 groups based on donor availability and their intentions.
Patients without an HLA-identical sibling or unrelated donor who did not
agree to receive haploidentical HSCT were assigned to a chemotherapy
group, referred to as group A, and continued to receive consolidation
chemotherapy for 1 to 1.5 years and then received maintenancechemotherapy for at least 1 year. However, patients without an HLA-
identical sibling or unrelated donor who agreed to receive haploidentical
HSCT were assigned to a haploidentical HSCT group, referred to as group B,
and continued to receive 0 to 2 cycles of consolidation chemotherapy and
then received haploidentical HSCT. Patients with an HLA-identical sibling or
unrelated donor who agreed to receive allo-HSCT received HLA-identical
sibling or unrelated HSCT and ﬁnally were excluded from this study
(Figure 1A). During follow-up, all patients received prophylaxis for central
nervous system (CNS) leukemia at regular intervals.
Chemotherapy procedure
The chemotherapy procedure for ALL patients consisted of induction,
consolidation, and maintenance chemotherapies. Induction chemotherapy
regimens included VDCLP (vincristine 1.5 mg/m2/d, days 1, 8, 15, and
22; daunorubicin 45 mg/m2/d, days 1 to 3 and days 15 to 17; cyclophos-
phamide [Cy] 800 mg/m2/d, days 1 and 15; prednisone 60 mg/m2/d, days 1
to 19; and L-asparaginase 10,000 U/m2/d, days 19 to 28) or VDLP (vincristine
1.5 mg/m2/d, days 1, 8, 15, and 22; daunorubicin 45mg/m2/d, days 1 to 3 and
days 15 to 17; prednisone 60 mg/m2/d, days 1 to 19; and L-asparaginase
10,000 U/m2/d, days 19 to 28). Consolidation chemotherapy regimens
included hyper-CVAD (B) (methotrexate [MTX] 1 g/m2/d, day 1; and cytosine
arabinoside [ara-C] 6 g/m2/d, days 2 to 7), hyper-CVAD (A) (Cy 600 mg/m2/d,
days 1 to 3; daunorubicin 50 mg/m2/d, days 4 to 5; vincristine 2 mg/m2/d,
day 4; and dexamethasone 40mg/d, days 1 to 4 and days 11 to 14), MTXþ L-
asparaginase (MTX 1 g/m2/d, day 1; and L-asparaginase 10,000 U/m2/d, days
2 to 8), or CAM (Cy 800 mg/m2/d, day 1; ara-C 100/m2/d, days 1 to 7; and
mercaptopurine 75 mg/m2/d p.o., days 1 to 7), which were given in turn.
Maintenance chemotherapy regimens consisted of mercaptopurine 50 mg/
m2/d p.o. daily and MTX 20 mg/m2/d p.o. weekly.
Transplant procedure and modiﬁed donor lymphocyte infusion procedure
The transplant procedure, including the conditioning regimen, graft-
versus-host disease (GVHD) prophylaxis, stem cell collection, and support-
ive care, was described in our previous report [9,10]. The drugs administered
in the conditioning regimens were as follows: ara-C (4 g/m2/d for 2 days),
busulfan (3.2 mg/kg/d i.v. for 3 days), Cy (1.8 g/m2/d for 2 days), simustine
(Me-CCNU, 250 mg/m2/d for 1 day), antihuman thymocyte immunoglobulin
(2.5 mg/kg/d for 4 days), and total body irradiation (770 cGy in a single
dose). The conditioning regimen was either a busulfan-based conditioning
regimen, which included ara-C (days 10 and 9), busulfan (days 8, 7,
and 6), Cy (days 5 and 4), antihuman thymocyte immunoglobulin
(days 5, 4, 3, and 2), and Me-CCNU (day 3), or a total body irradi-
ationebased conditioning regimen, which included total body irradiation
(day 6), Cy (days 5 and 4), antihuman thymocyte immunoglobulin
(days 5, 4, 3, and 2), and Me-CCNU (day 3). All patients received
granulocyte colony-stimulating factoremobilized bone marrow (BM) cells
plus peripheral blood stem cells. All transplant recipients received cyclo-
sporine A, mycophenolate mofetil, and short-term MTX for the prophylaxis
of GVHD.
If patients developed relapse or a status of minimal residual disease
(MRD)-positive post-transplant, they would receive modiﬁed donor
lymphocyte infusion (DLI) as described previously [14,15]. The procedure of
modiﬁed DLI consisted of the infusions of granulocyte colony-stimulating
factoremobilized peripheral blood stem cells and the application of
immunosuppressive agents after infusions to prevent DLI-associated GVHD.
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Prophylaxis of CNS leukemia consisted of intrathecal chemotherapy
with MTX, ara-C, and dexamethasone for at least 8 doses during induction
chemotherapy and consolidation chemotherapy.
MRD monitoring and deﬁnitions
MRD was monitored by using leukemia-associated aberrant immuno-
phenotypes (LAIPs) and leukemia-associated genes, such as WT1, E2A-PBX1,
and TEL-AML1, and other genes measured in the diagnostic specimens. LAIPs
were detected by 4-color ﬂow cytometry (FCM). Different antibody combi-
nations were used in B lineage and T lineage as described [16]. FCM-positive
was deﬁned as >.01% of cells with LAIPs in BM samples. The expression of
leukemia-associated genes was evaluated by TaqMan-based reverse tran-
scriptase PCR technology as described previously [17]. Leukemia-associated
geneepositive was deﬁned as a transcript level of reciprocal fusion genes >
104 or a transcript level ofWT1 > .60% in BM sample. Patients were scored
as MRD-positive if they had 1 positive result using FCM or PCR. After
achieving CR, MRD was monitored in all patients at regular intervals,
including at the time of achieving CR, after every cycle of consolidation
chemotherapy, and every 6 months during maintenance chemotherapy.
Deﬁnitions and Evaluation
Leukemia relapse was deﬁned as disease recurrence at any site after
achieving CR. FCM and molecular data were not used to deﬁne relapse. CR
was deﬁned as the absence of signs of leukemia, the absence of leukemic
blasts in peripheral blood samples, and <5% leukemic blasts in BM samples
without ongoing antileukemia chemotherapy. CNS leukemia was deﬁned as
unequivocal morphologic evidence of lymphoblasts in the cerebrospinal
ﬂuid using a cytocentrifuged sample, or cranial nerve palsies, or signiﬁcant
neurologic dysfunction [18,19]. Further cytogenetic subgroups in this study
were determined according to published data [20-23]. Adverse cytogenetic
subgroups included monosomy 7, trisomy 8, near triploidy, t(8;14), and
t(1;19). DFS was calculated from the date of CR until the date of ﬁrst relapse,
death from any cause, or the last follow-up for surviving patients after
achieving CR, whichever occurred ﬁrst. OS was measured from diagnosis
until the date of death from any cause or the last follow-up for surviving
patients.
Statistical Analyses
Cumulative incidences of relapse and treatment-related mortality were
calculated by accounting for competing risks [24]. DFS and OS were plotted
using the Kaplan-Meier method and were compared using the log-rank test
[25]. Univariate analyses were performed using the chi-square test for cat-
egorical variables and the Mann-Whitney test for continuous variables.
Multivariate analysis was performed using a Cox proportional hazards
model. All potential interacting variables were tested, screened out, and
extracted from the analysis. The endpoint of follow-up for all surviving
patients was December 31, 2013. Unless otherwise speciﬁed, all P values are
2-sided, and P< .05 was considered signiﬁcant. SPSS (http://www.spss.com/
) and R software (http://www.r-project.org/) packages were used for data
analyses.
RESULTS
Patients Groups
A series of consecutive 550 patients was diagnosed with
ALL at Peking University Institute of Hematology from
January 1, 2000 to May 30, 2013. Of those 550, 25 patients
lacking complete cytogenetic data at diagnosis were
excluded from this study. Of the remaining 525 patients, 328
patients did not meet the eligibility criteria and were
excluded from this study: 7 patients were <15 years old, 18
patients were >60 years old, 262 patients had high-risk
features of disease, 22 patients did not achieve CR after 2
cycles of induction chemotherapy, and 19 patients relapsed
after the second cycle of consolidation chemotherapy. Of the
remaining 197 patients, 59 patients receiving HLA-identical
related HSCT or unrelated HSCT were also excluded from
this study, and the other 138 patients were ﬁnally enrolled in
this study. Of these 138 patients, 59 patients received
chemotherapy alone (group A) and 79 patients received
haploidentical HSCT (group B) (Figure 1B). In group B, 7 pa-
tients received modiﬁed DLI because of relapse post-
transplant and 5 patients received modiﬁed DLI because ofMRD-positive status post-transplant. Table 1 shows the
characteristics of the 138 study patients.
Relapse, Treatment-Related Mortality, OS, and DFS
The cumulative incidence of relapse at 5 years in group A
was signiﬁcantly higher than that in group B (66.3% versus
29.9%, P < .0001). The incidence of treatment-related mor-
tality at 5 years was 9.8% in group A and 15.7% in group B (P¼
.057). Moreover, the OS and DFS in group A were also
signiﬁcantly inferior to those in group B (P < .0001 and P <
.0001, respectively) (Table 2 and Figure 2). Table 2 shows
incidences of acute GVHD, grades II to IV acute GVHD, grades
III to IV acute GVHD, chronic GVHD, and extensive chronic
GVHD post-transplant. From January 1, 2000 to May 30,
2013, 59 patients with standard-risk ALL in CR1 received
HLA-identical sibling HSCT or unrelated HSCT. The cumula-
tive incidence of relapse and treatment-related mortality at
5 years in these patients was 23.7% and 13.7%, respectively;
the OS and DFS at 5 years were 65.2% and 64.8%, respectively.
Risk Factors for Relapse and Risk Stratiﬁcation
The analysis of risk factors for relapse was only evaluated
in patients receiving chemotherapy alone (group A). On the
basis of univariate analysis, patient age (P ¼ .068), platelet
count at diagnosis (P ¼ .082), CNS leukemia (P ¼ .022), T cell
immunophenotype (P ¼ .043), expression of E2A-PBX1
(P ¼ .046), MRD-positive at the time of achieving CR (P ¼
.031), MRD-positive after the ﬁrst cycle of consolidation
chemotherapy (P ¼ .008), MRD-positive after the second
cycle of consolidation chemotherapy (P ¼ .090), and MRD-
positive at any time during consolidation chemotherapy
(P ¼ .025) were investigated by using Cox proportional
hazards model. Finally, CNS leukemia (P ¼ .002, hazard ratio
[HR] ¼ 8.039), T cell immunophenotype (P ¼ .044,
HR ¼ 3.985), expression of E2A-PBX1 (P ¼ .007, HR ¼ 20.014),
and MRD-positive after the ﬁrst cycle of consolidation
chemotherapy (P ¼ .004, HR ¼ 4.913) were signiﬁcantly
correlated with a cumulative risk of relapse in multivariate
analysis (Table 3).
According to the risk factors for relapse, 138 patients were
stratiﬁed into a low-risk group and a high-risk group. Fifty-
nine patients without any risk factors for relapse were
stratiﬁed into the low-risk group, and 61 patients with risk
factors were stratiﬁed into the high-risk group; the other 18
patients were not evaluated in this analysis because of a lack
of MRDmonitoring results during follow-up. The cumulative
incidence of relapse at 5 years in the low-risk group was
signiﬁcantly lower than that in the high-risk group (29.6%
versus 51.4%, P ¼ .010). The incidence of treatment-related
mortality at 5 years was 13.7% for the low-risk group and
9.8% for the high-risk group (P ¼ .619). Moreover, the OS and
DFS in the low-risk groupwere signiﬁcantly superior to those
in the high-risk group (P ¼ .020 and P ¼ .030, respectively)
(Table 4 and Figure 3).
Haploidentical HSCT Could Counteract the Unfavorable
Effects of Risk Stratiﬁcation
Based on the different risk stratiﬁcations and intervention
methods, 120 patients were further divided into 4 groups:
patients receiving chemotherapy in the low-risk group, pa-
tients receiving chemotherapy in the high-risk group, pa-
tients receiving HSCT in the low-risk group, and patients
receiving HSCT in the high-risk group. In the low-risk group,
there were no signiﬁcant differences in the incidence of
relapse, treatment-related mortality, OS, and DFS between
Table 1
Characteristics of All Patients (N ¼ 138)
Chemotherapy (Group A) Haploidentical HSCT (Group B) P
No. of patients 59 79
Patients age, yr (range) 24 (14-60) 24 (15-60) .808
Patients sex (%) .712
Male 31 (52.5) 39 (49.4)
Female 28 (47.5) 40 (50.6)
Disease types (%) .694
B lineage 49 (83.1) 61 (77.2)
T lineage 9 (15.3) 16 (20.3)
T lineage and B lineage 1 (1.7) 2 (2.5)
WBC count at diagnosis, 109/L, median (range) 6.06 (1.40-68.70) 5.50 (1.00-94.05) .914
Hemoglobin count at diagnosis, g/L, median (range) 87.0 (38.0-194.0) 83.0 (40.0-149.0) .389
Platelet count at diagnosis, 109/L, median (range) 77.0 (7.0-391.5) 82.0 (4.0-469.0) .616
Hepatomegaly (%) 3 (5.1) 4 (5.1) 1.000
Splenomegaly (%) 10 (16.9) 11 (13.9) .625
Lymph nodes enlargement (%) 17 (28.8) 12 (15.2) .052
Blasts in PB at diagnosis, 109/L, median (range) 1.00 (.00-21.50) .50 (.00-55.40) .969
Blasts in BM at diagnosis, %, median (range) .82 (.06-.98) .83 (.17-.97) .656
CNS leukemia (%) 5 (8.5) 4 (5.1) .497
Immunophenotype (%)
Pro-B 10 (16.9) 10 (12.7) .453
Com-B 33 (55.9) 41 (51.9) .562
Pre-B 5 (8.5) 10 (12.7) .271
Mature-B 1 (1.7) 0 (.0) .426
T cell 9 (15.3) 16 (20.3) .451
T cell and B cell 1 (1.7) 2 (2.5) 1.000
Molecular (%)
Expression of E2A-PBX1 2 (4.7) 3 (3.9) 1.000
Over-expression of WT1 22 (51.2) 35 (45.5) .548
Cytogenetic subgroups* (%) .479
Adverse 10 (16.9) 10 (12.7)
Other 49 (83.1) 69 (87.3)
Achieving CR at 14 d (%) 19 (82.6) 25 (73.5) .423
Time of achieving CR (%) .258
4 wk 55 (93.2) 69 (87.3)
8 wk 4 (6.8) 10 (12.7)
MRD-positive at the time of achieving CR (%) 16 (38.1) 29 (38.7) .951
MRD-positive after the ﬁrst cycle of consolidation chemotherapy (%) 9 (21.4) 25 (33.3) .171
MRD-positive after the second cycle of consolidation chemotherapy (%) 8 (19.0) 16 (21.3) .769
MRD-positive at any time during consolidation (%) 12 (28.6) 28 (37.3) .338
HLA-mismatch (%)
0 locus mismatch 1 (1.3)
1 locus mismatch 5 (6.3)
2 locus mismatch 32 (40.5)
3 locus mismatch 41 (51.9)
Type of haploidentical donor (%)
Sibling 32 (40.5)
Parents 41 (51.9)
Children 4 (5.1)
Nondirect relative (cousin, uncle, or nephew) 2 (2.5)
Median follow-up for surviving patients, mo (range) 14.03 (2.30-140.17) 32.78 (7.13-156.33) .013
PB indicates peripheral blood.
* Further cytogenetic subgroups in this study were determined according to published data [20-23]. Adverse cytogenetic subgroup included monosomy 7,
trisomy 8, near triploidy, t(8;14), and t(1;19).
Table 2
Outcomes of All Patients (N ¼ 138)
Chemotherapy (Group A) Haploidentical HSCT (Group B) P
No. of patients 59 79
Incidence of treatment-related mortality at 5 yr, % 9.8 15.7 .057
Actual relapse rate (%) 30 (50.8) 15 (19.0) .000
Incidence of relapse at 5 yr, % 66.3 29.9 .000
OS at 5 yr, % 28.0 70.4 .000
Mean OS, mo (95% CI) 52.22 (33.06-71.38) 115.17 (99.29-131.05) .000
DFS at 5 yr, % 23.9 54.4 .000
Mean DFS, mo (95% CI) 44.78 (27.57-61.99) 95.64 (76.48-114.80) .000
Incidence of acute GVHD, % 59.4
Incidence of grades II-IV acute GVHD, % 44.7
Incidence of grades III-IV acute GVHD, % 11.1
Incidence of chronic GVHD, % 52.7
Incidence of extensive chronic GVHD, % 21.5
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Figure 2. Relapse, treatment-related mortality, OS, and DFS in all patients (N ¼ 138). (A) Cumulative incidence of relapse. (B) Cumulative incidence of treatment-
related mortality. (C) OS. (D) DFS. Of the 138 patients enrolled in this study, 59 patients received chemotherapy alone (group A) and 79 patients received hap-
loidentical HSCT (group B).
C.-H. Yan et al. / Biol Blood Marrow Transplant 20 (2014) 1314e13211318chemotherapy and HSCT (relapse at 5 years: 32.7% versus
25.7%, P ¼ .122; treatment-related mortality at 5 years: 5.0%
versus 19.1%, P ¼ .276; OS at 5 years: 78.5% versus 73.1%, P ¼
.903; and DFS at 5 years: 62.3% versus 55.2%, P ¼ .497).
However, in the high-risk group, the incidence of relapse in
the chemotherapy group was statistically higher than that of
the HSCT group (P < .0001). OS and DFS at 2 years in the
chemotherapy group were .0% and .0%, respectively;Table 3
Risk Factors for Relapse in Patients Receiving Chemotherapy (Group A) (n ¼
59)
Univariate Analyses P
Patients age .068
Patients sex .902
Disease types .472
WBC count at diagnosis .127
Hemoglobin count at diagnosis .549
Platelet count at diagnosis .082
Hepatomegaly .237
Splenomegaly .299
Lymph nodes enlargement .711
Blasts in PB at diagnosis .629
Blasts in BM at diagnosis .743
CNS leukemia .022
Immunophenotype
Pro-B .487
Com-B .791
Pre-B .611
Mature-B 1.000
T cell .043
T cell and B cell .492
Molecular
Expression of E2A-PBX1 .046
Overexpression of WT1 .169
Cytogenetic subgroups* .299
Achieving CR at 14 d .260
Time of achieving CR 1.000
MRD-positive at the time of achieving CR .031
MRD-positive after the ﬁrst cycle of consolidation
chemotherapy
.008
MRD-positive after the second cycle of consolidation
chemotherapy
.090
MRD-positive at any time during consolidation .025
Multivariate analyses HR P
CNS leukemia 8.039 .002
T cell immunophenotype 3.985 .044
Expression of E2A-PBX1 20.014 .007
MRD-positive after the ﬁrst cycle of consolidation
chemotherapy
4.913 .004
PB indicates peripheral blood.
* Further cytogenetic subgroups in this study were determined according
to published data [20-23]. Adverse cytogenetic subgroups included mono-
somy 7, trisomy 8, near triploidy, t(8;14), and t(1;19).however, OS and DFS at 5 years in the HSCTgroupwere 70.5%
and 54.9%, respectively (P < .0001 and P < .0001). Moreover,
the incidences of relapse, treatment-related mortality, OS,
and DFS in patients receiving HSCT in the high-risk group
were all comparable with patients receiving chemotherapy
in the low-risk group (relapse at 5 years: 33.9% versus 32.7%,
P¼ .493; treatment-related mortality at 5 years: 11.2% versus
5.0%, P¼ .564; OS at 5 years: 70.5% versus 78.5%, P¼ .927; and
DFS at 5-year: 54.9% versus 62.3%, P ¼ .696) (Figure 4).DISCUSSION
Allo-HSCT has been widely used in adults with high-risk
ALL in CR1 because of its stronger antileukemia effects
than chemotherapy alone. Given the potent antileukemia
effects of allo-HSCT in ALL and the still-high relapse rate in
adult standard-risk ALL in CR1, some studies have already
supported HLA-identical sibling HSCT as the optimal post-
remission therapy in adult standard-risk patients in CR1. This
therapeutic method offers superior OS (HR ¼ .69; 95% con-
ﬁdence interval [CI], .45 to 1.06) and DFS (HR ¼ .66; 95% CI,
.43 to 1.00), signiﬁcantly reduces the risk of disease relapse
(HR ¼ .39; 95% CI, .29 to .53), and reduces mortality (relative
risk¼ .8; 95% CI, .68 to .94) [7,26,27]. However, a lack of HLA-
identical sibling or unrelated donor restricted the application
of allo-HSCT in adult standard-risk ALL patients in CR1. Our
previous results suggested that haploidentical HSCT was an
alternative therapeutic method for hematologic malig-
nancies and had comparable relapse rates, transplant-related
mortality, OS, and DFS with HLA-identical sibling HSCT
[9,10]. Moreover, our previous study also suggested that
haploidentical HSCT had stronger antileukemia effects thanTable 4
Outcomes of Patients Based on Risk Stratiﬁcation* (n ¼ 120)
Low-Risk Group High-Risk Group P
No. of patients 59 61
Incidence of
treatment-related
mortality at 5 yr, %
13.7 9.8 .619
Incidence of relapse
at 5 yr, %
29.6 51.4 .010
OS at 5 yr, % 75.2 51.5 .020
Mean OS, mo (95% CI) 72.74 (63.04-82.44) 61.92 (48.86-74.96) .020
DFS at 5 yr, % 56.7 38.7 .030
Mean DFS, mo (95% CI) 61.08 (50.01-72.16) 50.75 (37.44-64.05) .030
* According to the risk factors for relapse, 138 patients were stratiﬁed into
low-risk and high-risk groups. Fifty-nine patients without risk factors for
relapse were stratiﬁed into the low-risk group, 61 patients with risk factors
were stratiﬁed into the high-risk group, and 18 patients were not evaluated
in this analysis because of no MRD monitoring results during follow-up.
Figure 3. Relapse, treatment-related mortality, OS, and DFS of patients based on risk stratiﬁcation (N ¼ 120). (A) Cumulative incidence of relapse. (B) Cumulative
incidence of treatment-related mortality. (C) OS. (D) DFS. According to the risk factors for relapse, 138 patients were stratiﬁed into low-risk and high-risk groups.
Fifty-nine patients without risk factors for relapse were stratiﬁed into the low-risk group, 61 patients with risk factors were stratiﬁed into the high-risk group, and 18
patients were not evaluated in this analysis because of no MRD monitoring results during follow-up.
C.-H. Yan et al. / Biol Blood Marrow Transplant 20 (2014) 1314e1321 1319HLA-identical sibling HSCT in patients with refractory/
relapsed acute leukemia (relapse rate: 26% versus 49%, P ¼
.008) [28]. Taking into account the stronger antileukemia
effects and comparable transplant-related mortality, hap-
loidentical HSCT most likely beneﬁts adult standard-risk ALL
patients in CR1. This study is the ﬁrst to compare the efﬁcacy
and safety of haploidentical HSCT with chemotherapy alone
used as postremission therapy in adult standard-risk ALL
patients in CR1. Our present study suggested that compared
with chemotherapy alone, haploidentical HSCT had a lower
incidence of relapse (5-year: 29.9% versus 66.3%, P < .0001),
better OS and DFS (5-year OS: 70.4% versus 28.0%, P < .0001;
and 5-year DFS: 54.4% versus 23.9%, P < .0001), and com-
parable treatment-related mortality (5-year: 15.7% versus
9.8%, P ¼ .057). These results suggested that haploidentical
HSCT is most likely the better postremission therapy for
adults with standard-risk ALL in CR1.
Our study was not a prospective and randomized study;
however, all variables that were known to be correlated with
outcomes in this setting were comparable between the co-
horts, includingWBC count at diagnosis, immunophenotype,
adverse cytogenetic subgroup, CNS involvement, time of
achieving CR, status of MRD during follow-up, and so on.
Future randomized studies should be performed to compare
the efﬁcacy and safety of haploidentical HSCT and chemo-
therapy alone used as postremission therapy in adults with
standard-risk ALL in CR1.
Standard-risk ALL represents the major subgroup of adult
ALL. Although survival in these standard-risk patients in CR1
receiving haploidentical HSCT is estimated at an appreciable
70.4% at 5 years, those receiving chemotherapy aloneFigure 4. Relapse, treatment-related mortality, OS, and DFS of patients based on risk s
relapse. (B) Cumulative incidence of treatment-related mortality. (C) OS. (D) DFS. One
not evaluated because of no MRD monitoring results during follow-up. These 120 p
receiving chemotherapy (chemo-low, n ¼ 24), patients with risk factors and receiving c
HSCT (HSCT-low, n ¼ 35), and patients with risk factors and receiving HSCT (HSCT-high
comparison among chemo-low, HSCT-low, and HSCT-high.showed a 5-year survival of 28.0% (P < .0001). These results
may suggest that a yet unknown subcategory of standard-
risk patients may be cured by chemotherapy alone. Thus, it
is necessary to assess the risk of relapse before the decision
to receive haploidentical HSCT or chemotherapy alone is
made. However, the prognostic variables at diagnosis are
insufﬁcient to accurately identify the risk of relapse in those
standard-risk patients in CR1. Currently, the most promising
approach may be offered by the serial monitoring of MRD.
Some articles have already suggested that transcript levels of
WT1 or fusion genes detected by RT-PCR and LAIPs detected
by multicolor FCM could be used as MRD markers; the serial
monitoring of MRD using WT1, fusion gene, or LAIPs could
also predict the risk of relapse in ALL patients [29,30]. Our
present study suggested that CNS leukemia, the T cell
immunophenotype, expression of E2A-PBX1, and positive
MRD after the ﬁrst cycle of consolidation chemotherapy
were correlated with a higher risk of relapse (P < .05). Based
on these risk factors, adult patients with standard-risk ALL in
CR1 could be further stratiﬁed into high-risk and low-risk
patients. Patients with risk factors mentioned above (high-
risk patients) had higher relapse rates than those patients
without risk factors (low-risk patients) (51.4% versus 29.6%,
P ¼ .010) and also had inferior DFS rates (38.7% versus 56.7%,
P ¼ .030). These results suggested that on the basis of CNS
leukemia, T cell immunophenotype, expression of E2A-PBX1,
and positive MRD after the ﬁrst cycle of consolidation
chemotherapy, the establishment of risk stratiﬁcation could
identify the subgroup of patients with a higher risk of
relapse; different postremission therapeutic strategies could
be decided according to this risk stratiﬁcation.tratiﬁcation and intervention strategies (N ¼ 120). (A) Cumulative incidence of
hundred twenty patients were evaluated in this analysis, but 18 patients were
atients were further divided into 4 groups: patients without risk factors and
hemotherapy (chemo-high, n ¼ 20), patients without risk factors and receiving
, n ¼ 41). P1 represents the comparison among 4 groups, and P2 represents the
C.-H. Yan et al. / Biol Blood Marrow Transplant 20 (2014) 1314e13211320Our present study compared the efﬁcacy and safety of
different postremission therapeutic strategies in different
risk stratiﬁcation subgroups of adult patients with standard-
risk ALL in CR1. Our results suggested that in low-risk
patients, using chemotherapy alone was associated with
comparable relapse rates, treatment-related mortality, OS,
and DFS with haploidentical HSCT (5-year relapse: 32.7%
versus 25.7%, P ¼ .122; 5-year treatment-related mortality:
5.0% versus 19.1%, P¼ .276; 5-year OS: 78.5% versus 73.1%, P¼
.903; and 5-year DFS: 62.3% versus 55.2%, P ¼ .497). Never-
theless, in high-risk patients, using chemotherapy alone was
only associated with a 2-year OS of .0% and a 2-year DFS of
.0%. On the contrary, using haploidentical HSCT in high-risk
patients was associated with comparable OS and DFS with
using haploidentical HSCT in low-risk patients or chemo-
therapy alone in low-risk patients (P > .05). These results
suggested that risk stratiﬁcationedirected postremission
therapeutic strategies using chemotherapy alone or hap-
loidentical HSCT not only reduced relapse risk, but also
avoided unnecessary treatment-relatedmortality induced by
haploidentical HSCT and improved survival in adult patients
with standard-risk ALL in CR1. A randomized study should be
performed to conﬁrm these results.
Treatment-related mortality, especially due to severe
GVHD post-transplant, is an important complication of
haploidentical HSCT and impedes the application of this
treatment. However, as the haploidentical HSCT technique
improves, transplant-related mortality is only approximately
18%, the incidence of grades II to IV acute GVHD after hap-
loidentical HSCT is 43%, and the incidence of chronic GVHD is
53% [10]. All these results are comparable with HLA-identical
sibling HSCT (treatment-related mortally: 22% versus 14%,
P ¼ .10; grades II to IV acute GVHD: 40% versus 32%, P ¼ .13;
chronic GVHD: 55% versus 56%, P ¼ .90) [9]. Our present
study also suggested that treatment-related mortality at
5 years in the haploidentical HSCT group was only 15.7%. The
incidences of acute GVHD, grades II to IV acute GVHD, grades
III to IV acute GVHD, chronic GVHD, and extensive chronic
GVHD after haploidentical HSCT were 59.4%, 44.7%, 11.1%,
52.7% and 21.5%, respectively.
In conclusion, our study is the ﬁrst to compare the efﬁcacy
and safety of haploidentical HSCT with chemotherapy alone
usedaspostremission therapy inadultpatientswith standard-
risk ALL in CR1. Our results suggest that haploidentical HSCT
could beneﬁt adult patientswith standard-riskALL in CR1. Our
study also demonstrates that CNS leukemia, T cell immuno-
phenotype, expression of E2A-PBX1, and positive MRD after
the ﬁrst cycle of consolidation chemotherapy are the risk
factors of relapse. On the basis of these risk factors, the
establishment of risk stratiﬁcation for adult patients with
standard-risk ALL in CR1 could identify the subgroup of pa-
tients with a higher risk of relapse. Furthermore, our results
conﬁrm that risk stratiﬁcationedirected postremission ther-
apies using haploidentical HSCT or chemotherapy alone not
only reduce the relapse rate, but also avoid unnecessary
treatment-related mortality induced by haploidentical HSCT
and ﬁnally improve survival in adult patients with standard-
risk ALL in CR1.ACKNOWLEDGMENTS
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